STOCK TITAN

IGM Biosciences Inc - IGMS STOCK NEWS

Welcome to our dedicated news page for IGM Biosciences (Ticker: IGMS), a resource for investors and traders seeking the latest updates and insights on IGM Biosciences.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect IGM Biosciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of IGM Biosciences's position in the market.

Rhea-AI Summary
Medivir AB (MVIR) to Present at Erik Penser Bank Company Event on November 23
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.68%
Tags
conferences
-
Rhea-AI Summary
IGM Biosciences, Inc. (Nasdaq: IGMS) Announces Third IND Cleared for Imvotamab in Autoimmune Diseases and International Sites Opened for Aplitabart Randomized Clinical Trial. The company presents its financial results for the quarter ended September 30, 2023, highlighting progress in clinical development, pipeline products, and 2023 financial guidance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.09%
Tags
-
Rhea-AI Summary
Medivir AB (Nasdaq Stockholm: MVIR) announces the presentation of clinical data from the phase 1b/2a study of fostrox in combination with Lenvima at the ASCO Gastrointestinal Cancers Symposium. The FDA interactions for fostrox's clinical development plan have intensified, with a positive response for the planned phase 2b study design.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.1%
Tags
conferences clinical trial
Rhea-AI Summary
IGM Biosciences, Inc. (Nasdaq: IGMS) announced that CEO Fred Schwarzer will present at the Stifel Healthcare Conference on November 14 and the Jefferies London Healthcare Conference on November 16. The presentations will be available via live webcast on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.43%
Tags
conferences
-
Rhea-AI Summary
Medivir AB plans to report new and updated data from its ongoing phase 2a study with the candidate drug fostrox in combination with Lenvima® in advanced hepatocellular carcinoma (HCC). The data will focus on the 18 out of 21 total patients that have had a minimum follow-up of 12 weeks. The data update will be part of Medivir's interim report for the third quarter on Friday, October 27, 2023, followed by a comprehensive update in a webcasted presentation at 14.00 CET the same day.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.67%
Tags
conferences clinical trial
-
Rhea-AI Summary
Medivir AB announces appointment of nomination committee for Annual General Meeting in 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.06%
Tags
none
News
Rhea-AI Summary
Medivir AB board member Anette Lindqvist resigns due to personal reasons
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.9%
Tags
management
-
Rhea-AI Summary
Medivir AB announces promising clinical benefit in ongoing phase 2a study for advanced hepatocellular carcinoma
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.26%
Tags
none
-
Rhea-AI Summary
IGM Biosciences announces retirement of Dr. Michael Loberg from Board of Directors and appointment of Dr. Elizabeth H.Z. Thompson as new board member.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.66%
Tags
management
Rhea-AI Summary
Medivir to present at the Pareto Securities Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.28%
Tags
conferences
IGM Biosciences Inc

Nasdaq:IGMS

IGMS Rankings

IGMS Stock Data

538.49M
11.53M
35.23%
68.07%
8.88%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Mountain View

About IGMS

igm biosciences, inc., a biotechnology company, engages in the research and development of immunoglobulin m (igm) antibodies for the treatment of cancer. the company's lead product candidate is igm-2323, a bispecific igm antibody that is in phase 1 clinical trials to treat patients with b cell nhl and other b cell malignancies. it is also developing igm-8444, an igm antibody targeting death receptor 5 proteins; and igm-7354, is a bispecific igm antibody delivering interleukin-15 cytokines to pd-l1 expressing cells for use in the treatment of patients with solid and hematologic malignancies. igm biosciences, inc. has a collaboration with atreca inc. and beigene ltd. to discover, develop, and manufacture novel igm and iga antibodies targeting sars-cov-2 for the potential treatment of covid-19; and strategic research collaboration and license agreement with abcellera to discover and develop igm antibodies. the company was formerly known as palingen, inc. and changed its name to igm biosci